Active Biotech AB Interim report January - March 2015

(Thomson Reuters ONE) -



Laquinimod
* The pivotal CONCERTO clinical study is continuing according to plan and
results are expected in 2016
* Teva is holding a number of presentations of laquinimod at the AAN Annual
Meeting on April 18-25

Tasquinimod
* Results from the Phase III study 10TASQ10 showed that treatment with
tasquinimod reduced the risk of radiographic cancer progression or death
compared to placebo (rPFS, HR=0.69, CI 95%: 0.60 - 0.80) in patients with
metastatic castration resistant prostate cancer (mCRPC) who have not
received chemotherapy, but did not extend overall survival (OS, HR=1.09, CI
95%: 0.94 - 1.28)
* Further development of tasquinimod for the treatment of prostate cancer has
been discontinued. The collaboration agreement with Ipsen will accordingly
cease.


ISI
* The project is currently focusing on building up a patent portfolio


Financial summary

MSEK   Jan. - Mar.   Jan. - Dec.

  2015 2014   2014
-------------------------------------------------------
Net sales 2.9 2.1   10.4



Operating loss -57.4 -59.2   -228.5

Loss for the period -58.0 -60.2   -231.5

Loss per share (SEK) -0.64 -0.80   -3.02

Cash and cash equivalents  270.5 298.5   328.5



 For further information, please contact:

  Tomas Leanderson, President and CEO Active Biotech AB
  Tel: +46 (0)46 19 20 95 (Corp. Reg. No. 556223-9227)
  Box 724, SE-220 07 Lund
  Hans Kolam, CFO Tel: +46 (0)46 19 20 00
  Tel: +46 (0)46 19 20 44 Fax: +46 (0)46 19 11 00

  The report is also available at
www.activebiotech.com


Active Biotech AB Interim report January - March 2015:
http://hugin.info/1002/R/1913651/683571.pdf



This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.

Source: Active Biotech via GlobeNewswire
[HUG#1913651]

Weitere Infos zu dieser Pressemeldung:
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
Datum: 23.04.2015 - 08:31 Uhr
Sprache: Deutsch
News-ID 387968
Anzahl Zeichen: 2785

contact information:
Town:

LUND

Kategorie:

Business News

Diese Pressemitteilung wurde bisher 195 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Active Biotech AB Interim report January - March 2015"
steht unter der journalistisch-redaktionellen Verantwortung von

Active Biotech (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Primary endpoint reached in Active Biotech's TASQ Phase II clinical trial i ...

Lund, Sweden, December 14, 2009 - A first analysis of the primary endpoint based on data from at least six months' treatment of more than 200 patients, has been performed in Active Biotech AB's (NASDAQ OMX Nordic: ACTI) ongoing Phase II cli ...

Active Biotech's election committee appointed ...

In accordance with a decision made by the Annual General Meeting held on May 7, 2009, the Election Committee shall comprise the representatives for the three largest shareholders on September 30 and the Board Chairman. For the 2010 Annual General ...

Active Biotech AB Interim Report, January - September 2009 ...

* Laquinimod -- new data presented at ECTRIMS * 57-57 -- exploratory clinical trial in progress * RhuDex(TM) -- clinical development to continue following feedback from UK MHRA * ANYARA -- complete Phase I data published * TASQ -- complete Phase I ...

Alle Meldungen von Active Biotech